Loading clinical trials...
Loading clinical trials...
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Conditions
Interventions
Toca 511
Toca FC
+3 more
Locations
67
United States
Barrow Neurological Institute at Dignity Health St. Joseph's Hospital and Medical Center
Phoenix, Arizona, United States
University of California, Irvine
Irvine, California, United States
University of California San Diego
La Jolla, California, United States
University of California, Los Angeles
Los Angeles, California, United States
St. Joseph Hospital
Orange, California, United States
University of California San Francisco
San Francisco, California, United States
Start Date
November 30, 2015
Primary Completion Date
May 31, 2019
Completion Date
December 20, 2019
Last Updated
February 7, 2020
NCT02800486
NCT05839379
NCT00083512
NCT07100730
NCT05281731
NCT07391215
Lead Sponsor
Tocagen Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions